» Articles » PMID: 38878186

Disrupting Smad3 Potentiates Immunostimulatory Function of NK Cells Against Lung Carcinoma by Promoting GM-CSF Production

Overview
Publisher Springer
Specialty Biology
Date 2024 Jun 15
PMID 38878186
Authors
Affiliations
Soon will be listed here.
Abstract

Through Smad3-dependent signalings, transforming growth factor-β (TGF-β) suppresses the development, maturation, cytokine productions and cytolytic functions of NK cells in cancer. Silencing Smad3 remarkably restores the cytotoxicity of NK-92 against cancer in TGF-β-rich microenvironment, but its effects on the immunoregulatory functions of NK cells remain obscure. In this study, we identified Smad3 functioned as a transcriptional repressor for CSF2 (GM-CSF) in NK cells. Therefore, disrupting Smad3 largely mitigated TGF-β-mediated suppression on GM-CSF production by NK cells. Furthermore, silencing GM-CSF in Smad3 knockout NK cells substantially impaired their anti-lung carcinoma effects. In-depth study demonstrated that NK-derived GM-CSF strengthened T cell immune responses by stimulating dendritic cell differentiation and M1 macrophage polarization. Meanwhile, NK-derived GM-CSF promoted the survival of neutrophils, which in turn facilitated the terminal maturation of NK cells, and subsequently boosted NK-cell mediated cytotoxicity against lung carcinoma. Thus, Smad3-silenced NK-92 (NK-92-S3KD) may serve as a promising immunoadjuvant therapy with clinical translational value given its robust cytotoxicity against malignant cells and immunostimulatory functions to reinforce the therapeutic effects of other immunotherapies.

Citing Articles

Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy.

Dehghan F, Metanat Y, Askarizadeh M, Ahmadi E, Moradi V Front Cell Dev Biol. 2025; 12:1511931.

PMID: 40007761 PMC: 11850336. DOI: 10.3389/fcell.2024.1511931.


Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial.

Ni J, Wang X, Wu L, Ai X, Chu Q, Han C Nat Commun. 2024; 15(1):7242.

PMID: 39174542 PMC: 11341907. DOI: 10.1038/s41467-024-51807-7.

References
1.
Locatelli F, Pende D, Falco M, Della Chiesa M, Moretta A, Moretta L . NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia. Trends Immunol. 2018; 39(7):577-590. DOI: 10.1016/j.it.2018.04.009. View

2.
Newton R, King E, Gong W, Rider C, Staples K, Holden N . Glucocorticoids inhibit IL-1beta-induced GM-CSF expression at multiple levels: roles for the ERK pathway and repression by MKP-1. Biochem J. 2010; 427(1):113-24. DOI: 10.1042/BJ20091038. View

3.
Singhal S, Bhojnagarwala P, OBrien S, Moon E, Garfall A, Rao A . Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. Cancer Cell. 2016; 30(1):120-135. PMC: 4945447. DOI: 10.1016/j.ccell.2016.06.001. View

4.
Pei X, Nakanishi Y, Takayama K, Bai F, Hara N . Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer. 1999; 79(1):40-6. PMC: 2362164. DOI: 10.1038/sj.bjc.6690009. View

5.
Yamashita Y, Nara N, Aoki N . Antiproliferative and differentiative effect of granulocyte-macrophage colony-stimulating factor on a variant human small cell lung cancer cell line. Cancer Res. 1989; 49(19):5334-8. View